Combination of nivolumab (nivo) plus ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study.

被引：20
|
作者：
Andre, Thierry
Lonardi, Sara
Wong, Ka Yeung Mark
Morse, Michael
McDermott, Raymond S.
Hill, Andrew Graham
Hendlisz, Alain
Lenz, Heinz-Josef
Leach, Joseph W.
Moss, Rebecca Anne
Cao, Z. Alexander
Ledeine, Jean-Marie
Chan, Emily
Kopetz, Scott
Michael, J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3531
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
    Ambrosini, M.
    Tougeron, D.
    Modest, P.
    Guimbaud, R.
    Kopetz, S.
    Decraecker, M.
    Sclafani, F.
    Coutzac, C.
    Lievre, A.
    Alouani, E. L.
    Marmorino, F.
    Pernot, S.
    Sinicrope, A.
    Elez Fernandez, E.
    Germani, M. M.
    Pietrantonio, F.
    Lonardi, S.
    Parent, P.
    Gallois, C.
    Taieb, J.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S32 - S32
  • [42] Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Vaghi, C.
    Ros Montana, F. J.
    Mambrilla, M.
    Navarro Garces, V.
    Comas, R.
    Salva Ballabrera, F.
    Baraibar Argota, I.
    Saoudi Gonzalez, N.
    Rodriguez Castells, M.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Tabernero, J.
    Elez Fernandez, M. E.
    [J]. ANNALS OF ONCOLOGY, 2024, 35 : S56 - S57
  • [43] Pembrolizumab (pembro) for previously treated, microsatellite instabilityehigh (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Final analysis of KEYNOTE-164
    Le, D. T.
    Diaz, L.
    Kim, T. W.
    Van Cutsem, E.
    Geva, R.
    Jager, D.
    Hara, H.
    Burge, M.
    O'Neil, B.
    Kavan, P.
    Yoshino, T.
    Guimbaud, R.
    Taniguchi, H.
    Elez, E.
    Al-Batran, S-E.
    Boland, P.
    Cui, Y.
    Leconte, P.
    Marinello, P.
    Andre, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S550 - S550
  • [44] Clinicopathological and genomic characteristics of DNA Mismatch Repair-Deficient (dMMR) and microsatellite instability-high (MSI-H) resected gastric adenocarcinoma
    Zhou, J.
    Liang, B.
    Yin, M.
    Zhang, H.
    Liu, F.
    Dong, L.
    Zhang, B.
    Xu, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S921 - S922
  • [45] Phase 1b/2 study of binimetinib (BINI) in combination with nivolumab (NIVO) or NIVO plus ipilimumab (IPI) in patients (pts) with previously treated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) with RAS mutation.
    Bendell, Johanna C.
    Kopetz, Scott
    Middleton, Mark R.
    Eves, P. Taylor
    Bozon, Viviana
    Boyd, Adam P.
    Schellens, Jan H. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] Pembrolizumab in microsatellite instability high (MSI-H)/ mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.
    Maio, Michele
    Ascierto, Paolo Antonio
    Manzyuk, Ludmila
    Motola-Kuba, Daniel
    Penel, Nicolas
    Cassier, Philippe A.
    Bariani, Giovanni
    De Jesus-Acosta, Ana
    Doi, Toshihiko
    Longo, Federico
    Miller, Wilson H.
    Oh, Do-Youn
    Gottfried, Maya
    Wang, Ruixue
    Jin, Fan
    Norwood, Kevin Glen
    Marabelle, Aurelien
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.
    Kawazoe, Akihito
    Shitara, Kohei
    Noguchi, Masaaki
    Fukuoka, Shota
    Kuboki, Yasutoshi
    Bando, Hideaki
    Okamoto, Wataru
    Kojima, Takashi
    Doi, Toshihiko
    Ohtsu, Atsushi
    Yoshino, Takayuki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [48] Potential drug cost impact of nivolumab (N) in Canada in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
    Virik, Kiran
    Biagi, James Joseph
    Wilson, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
    Andre, T.
    Lonardi, S.
    Wong, K. Y. M.
    Lenz, H. -J
    Gelsomino, F.
    Aglietta, M.
    Van Cutsem, E.
    McDermott, R.
    Hill, A.
    Sawyer, M. B.
    Hendlisz, A.
    Neyns, B.
    Abdullaev, S.
    Memaj, A.
    Lei, M.
    Dixon, M.
    Kopetz, S.
    Overman, M. J.
    Morse, M. A.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (10) : 1052 - 1060
  • [50] Potential drug cost impact of dual agent immunotherapy (DAIO) with nivolumab (N) plus ipilimumab (I) in patients with DNA mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) in Canada
    Virik, K.
    Wilson, R. B.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 434 - 434
12345